Mental Health Drives Life Quality in Treated Hypothyroidism
METHODOLOGY:
Levothyroxine monotherapy to normalise serum thyrotropin (TSH) is the standard treatment for primary hypothyroidism and greatly improves symptoms and life expectancy, yet at least 10%-15% of patients still experience persistent symptoms and reduced QOL despite having normal TSH levels.
Researchers conducted a cross-sectional study (August 2021 to 2022) to examine predictors of QOL in 157 adults (mean age, 49.5 years) with primary hypothyroidism for more than 2 years who were free of major comorbidities and had been on a stable dose of levothyroxine monotherapy and maintained a normal TSH level for more than 6 months; 70.7% of participants had autoimmune thyroiditis and 29.3% had iatrogenic hypothyroidism.
Levels of various thyroid-specific biomarkers such as TSH, free tissue triiodothyronine, and free thyroxine were measured.
Participants completed the Underactive Thyroid-Dependent Quality of Life Questionnaire and Underactive Thyroid Symptom Rating Questionnaire to assess thyroid-dependent QOL and the number of hypothyroidism symptoms; other validated questionnaires were used to measure depressive symptoms and somatosensory amplification.
TAKEAWAY:
The negative impact of hypothyroidism on QOL was most evident in women and participants with higher BMI, autoimmune thyroiditis, greater somatosensory amplification, more severe depression, and a higher count of hypothyroidism-related symptoms.
None of the thyroid-specific biomarkers were associated with thyroid-dependent QOL.
In the final model, significant predictors of thyroid-dependent QOL were somatosensory amplification ( P = .002), BMI ( P = .021), and depression ( P < .001).
IN PRACTICE:
"When considered collectively, our findings are consistent with the theory that once TSH is normalized, thyroid-dependent QoL is primarily influenced by unrecognized comorbidities such as obesity, somatic symptom disorder, and depression," the authors wrote.
SOURCE:
This study was led by Bence Bakos, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary. It was published online on May 26, 2025, in BMC Endocrine Disorders .
LIMITATIONS:
Researchers could not establish causality owing to the cross-sectional design of this study.
DISCLOSURES:
This study did not receive any specific grant from any funding agency. The authors declared having no conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
03-06-2025
- Medscape
Mental Health Drives Life Quality in Treated Hypothyroidism
In patients with primary hypothyroidism receiving a stable dose of levothyroxine, thyroid-dependent quality of life (QOL) was driven by psychological factors, including somatosensory amplification and depression, and body mass index (BMI), rather than by thyroid biomarkers. METHODOLOGY: Levothyroxine monotherapy to normalise serum thyrotropin (TSH) is the standard treatment for primary hypothyroidism and greatly improves symptoms and life expectancy, yet at least 10%-15% of patients still experience persistent symptoms and reduced QOL despite having normal TSH levels. Researchers conducted a cross-sectional study (August 2021 to 2022) to examine predictors of QOL in 157 adults (mean age, 49.5 years) with primary hypothyroidism for more than 2 years who were free of major comorbidities and had been on a stable dose of levothyroxine monotherapy and maintained a normal TSH level for more than 6 months; 70.7% of participants had autoimmune thyroiditis and 29.3% had iatrogenic hypothyroidism. Levels of various thyroid-specific biomarkers such as TSH, free tissue triiodothyronine, and free thyroxine were measured. Participants completed the Underactive Thyroid-Dependent Quality of Life Questionnaire and Underactive Thyroid Symptom Rating Questionnaire to assess thyroid-dependent QOL and the number of hypothyroidism symptoms; other validated questionnaires were used to measure depressive symptoms and somatosensory amplification. TAKEAWAY: The negative impact of hypothyroidism on QOL was most evident in women and participants with higher BMI, autoimmune thyroiditis, greater somatosensory amplification, more severe depression, and a higher count of hypothyroidism-related symptoms. None of the thyroid-specific biomarkers were associated with thyroid-dependent QOL. In the final model, significant predictors of thyroid-dependent QOL were somatosensory amplification ( P = .002), BMI ( P = .021), and depression ( P < .001). IN PRACTICE: "When considered collectively, our findings are consistent with the theory that once TSH is normalized, thyroid-dependent QoL is primarily influenced by unrecognized comorbidities such as obesity, somatic symptom disorder, and depression," the authors wrote. SOURCE: This study was led by Bence Bakos, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary. It was published online on May 26, 2025, in BMC Endocrine Disorders . LIMITATIONS: Researchers could not establish causality owing to the cross-sectional design of this study. DISCLOSURES: This study did not receive any specific grant from any funding agency. The authors declared having no conflicts of interest.
Yahoo
19-04-2025
- Yahoo
Colorectal cancer risk reduced by this common vitamin, study suggests
Vitamin D is widely known for boosting bone health, muscle strength and immune function, but it also has a range of other benefits — including cancer prevention. A new study published in the journal Nutrients suggests that the common vitamin is effective in preventing and treating colorectal cancer. Hungarian researchers conducted a meta-analysis of 50 previous studies that included more than 1.3 million participants, focusing on vitamin D's potential effects on cancer risk, immunity and inflammation. Common Vitamin Shown To Reduce Autoimmune Disease "The most important finding is that vitamin D plays a critical role in the prevention and treatment of colorectal cancer," study author János Tamás Varga, PhD, associate professor at Semmelweis University in Budapest, told Fox News Digital. "Our research clearly supports the strong correlation between 25-hydroxyvitamin D (the primary form of vitamin D) levels and cancer outcomes." Read On The Fox News App Cancer patients with low vitamin D levels showed poorer prognoses. Vitamin D has been shown to reduce inflammation, promote the death of cancer cells, inhibit tumor growth and enhance immune response, the researchers found. Vitamin D Deficiency Linked To Dementia In Certain Populations When Levels Are Very Low: Study "These mechanisms significantly influence the pathophysiology of colorectal cancer," Varga noted. In addition to prevention, vitamin D supplementation was also shown to improve survival rates among patients with advanced-stage colorectal cancer, according to the research. "The results suggest that the effect of vitamin D may depend on factors such as the dosage, the individual condition of the patients and the duration of treatment," Vargas added. The American Cancer Society (ACS) has previously referenced studies suggesting that vitamin D could lower cancer risk, particularly colorectal cancer. "However, large studies have not found that vitamin D supplements lower the risk of colorectal polyps (pre-cancerous growths) or cancer," the ACS stated on its website. One important limitation of the research is that the studies included in the analysis used different vitamin D dosages and involved patients at various stages of cancer, the authors noted. They called for further research to accurately determine the optimal dosage and "therapeutic efficacy." "Based on our research, we recommend that individuals at high risk of colorectal cancer monitor their vitamin D levels and, if necessary, take a daily vitamin D supplement of 1000–4000 IU, especially for those with low vitamin D levels," lead study author Dr. Monika Fekete, medical doctor at Semmelweis University, told Fox News Digital. "The optimal dosage should be tailored to the individual's health condition and current vitamin D levels." For physicians, the researchers suggest routinely measuring and supplementing vitamin D levels for both prevention and treatment purposes. "Vitamin D plays a crucial role in the treatment and prevention of colorectal cancer, but further research is needed to determine the optimal dosage and the specific role of genetic factors," Fekete added. "The molecular mechanisms of vitamin D — such as the regulation of oncogenes (mutated genes that can lead to cancer) and inhibition of tumor progression — require further scientific investigation." As the effect of vitamin D is closely linked to the patient's condition, the doctor said, treatment recommendations should be personalized. Click Here To Sign Up For Our Health Newsletter The primary source of vitamin D is exposure to the sun's ultraviolet (UV) rays. It can also be obtained from dietary sources, according to the ACS, including fatty fish and some mushrooms. There are also some vitamin D-fortified foods, including milk, some orange juices and cereals, the above source stated. People can also take vitamin D supplements to boost their levels. For more Health articles, visit "Most Americans do not get enough vitamin D in their diets, and many have low vitamin D levels in their blood," the ACS said on its website. "While the role of vitamin D in lowering cancer risk is still an active area of research and debate, avoiding low vitamin D levels is recommended."Original article source: Colorectal cancer risk reduced by this common vitamin, study suggests
Fox News
19-04-2025
- Fox News
Colorectal cancer risk reduced by this common vitamin, study suggests
Vitamin D is widely known for boosting bone health, muscle strength and immune function, but it also has a range of other benefits — including cancer prevention. A new study published in the journal Nutrients suggests that the common vitamin is effective in preventing and treating colorectal cancer. Hungarian researchers conducted a meta-analysis of 50 previous studies that included more than 1.3 million participants, focusing on vitamin D's potential effects on cancer risk, immunity and inflammation. "The most important finding is that vitamin D plays a critical role in the prevention and treatment of colorectal cancer," study author János Tamás Varga, PhD, associate professor at Semmelweis University in Budapest, told Fox News Digital. "Our research clearly supports the strong correlation between 25-hydroxyvitamin D (the primary form of vitamin D) levels and cancer outcomes." Cancer patients with low vitamin D levels showed poorer prognoses. Vitamin D has been shown to reduce inflammation, promote the death of cancer cells, inhibit tumor growth and enhance immune response, the researchers found. "These mechanisms significantly influence the pathophysiology of colorectal cancer," Varga noted. In addition to prevention, vitamin D supplementation was also shown to improve survival rates among patients with advanced-stage colorectal cancer, according to the research. "The results suggest that the effect of vitamin D may depend on factors such as the dosage, the individual condition of the patients and the duration of treatment," Vargas added. The American Cancer Society (ACS) has previously referenced studies suggesting that vitamin D could lower cancer risk, particularly colorectal cancer. "However, large studies have not found that vitamin D supplements lower the risk of colorectal polyps (pre-cancerous growths) or cancer," the ACS stated on its website. "The optimal dosage should be tailored to the individual's health condition and current vitamin D levels." One important limitation of the research is that the studies included in the analysis used different vitamin D dosages and involved patients at various stages of cancer, the authors noted. They called for further research to accurately determine the optimal dosage and "therapeutic efficacy." "Based on our research, we recommend that individuals at high risk of colorectal cancer monitor their vitamin D levels and, if necessary, take a daily vitamin D supplement of 1000–4000 IU, especially for those with low vitamin D levels," lead study author Dr. Monika Fekete, medical doctor at Semmelweis University, told Fox News Digital. "The optimal dosage should be tailored to the individual's health condition and current vitamin D levels." For physicians, the researchers suggest routinely measuring and supplementing vitamin D levels for both prevention and treatment purposes. "Vitamin D plays a crucial role in the treatment and prevention of colorectal cancer, but further research is needed to determine the optimal dosage and the specific role of genetic factors," Fekete added. "The molecular mechanisms of vitamin D — such as the regulation of oncogenes (mutated genes that can lead to cancer) and inhibition of tumor progression — require further scientific investigation." As the effect of vitamin D is closely linked to the patient's condition, the doctor said, treatment recommendations should be personalized. The primary source of vitamin D is exposure to the sun's ultraviolet (UV) rays. It can also be obtained from dietary sources, according to the ACS, including fatty fish and some mushrooms. There are also some vitamin D-fortified foods, including milk, some orange juices and cereals, the above source stated. People can also take vitamin D supplements to boost their levels. "Most Americans do not get enough vitamin D in their diets, and many have low vitamin D levels in their blood," the ACS said on its website. "While the role of vitamin D in lowering cancer risk is still an active area of research and debate, avoiding low vitamin D levels is recommended."
